Combination of rituximab and abatacept as an exit strategy for repetitive B-cell depletion in children with severe autoimmune diseases: a report of three cases
Restricted accessLetterFirst published online October, 2018
Combination of rituximab and abatacept as an exit strategy for repetitive B-cell depletion in children with severe autoimmune diseases: a report of three cases
WalkerLSK. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun2013; 45: 49–57.
2.
Picchianti DiamantiARosadoMMScarsellaMet al.Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents. Clin Exp Immunol2014; 177: 630–640.
3.
VerstappenGMMeinersPMCornethOBJet al.Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sjögren’s syndrome. Arthritis Rheumatol Hoboken NJ2017; 69: 1850–1861.
4.
RazmaraMHilliardBZiaraniAKChenYHTykocinckiML. CTLA-4 × Ig converts naive CD4+CD25-T cells into CD4+CD25+ regulatory T cells. Int Immunol2008; 20: 471–483.
5.
ChenJWangQYinDVuVSciammasRChongAS. Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients. J Immunol Baltimore Med 19502015; 195: 4069–4073.
6.
ScarsiMPaoliniLRicottaDet al.Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol2014; 41: 666–672.
7.
IwataSNakayamadaSFukuyoSet al.Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. Arthritis Rheumatol Hoboken NJ2015; 67: 63–73.
8.
Pimentel-QuirozVRUgarte-GilMFAlarcónGS. Abatacept for the treatment of systemic lupus erythematosus. Expert Opin Investig Drugs2016; 25: 493–499.
